{
    "clinical_study": {
        "@rank": "48543", 
        "arm_group": [
            {
                "arm_group_label": "Breast Cancer"
            }, 
            {
                "arm_group_label": "Healthy"
            }
        ], 
        "brief_summary": {
            "textblock": "Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the\n      Spectrosense EVA system, which is combination of a gas chromatography (GC) and software\n      algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the\n      best discrimination between Breast Cancer sick population and healthy population. The gold\n      standard for identifying sick/healthy population is biopsy proven breast cancer."
        }, 
        "brief_title": "Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Breast Cancer group:\n\n        Inclusion Criteria:\n\n          -  Age from 18 years old\n\n          -  Breast cancer positive biopsy\n\n          -  Before  any treatment\n\n          -  Signed Informed Patient Consent\n\n        Exclusion Criteria:\n\n          -  Age under 18 years old\n\n          -  Neoadjovant treatment\n\n          -  Post surgery for breast cancer\n\n          -  A history of any other cancer type, except skin cancer that is not melanoma\n\n        Healthy group:\n\n        Inclusion Criteria:\n\n          -  Healthy women\n\n          -  No history of Breast cancer\n\n          -  Signed Informed Patient Consent\n\n        Exclusion Criteria:\n\n          -  History of Breast cancer\n\n          -  Breast cancer background in the family\n\n          -  A history of any other cancer type, except skin cancer that is not melanoma"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Women with breast cancer, biopsy confirmed, ages above 18. vs. Healthy women without\n        breast cancer."
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849328", 
            "org_study_id": "E-13-492"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Englewood", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07631"
                }, 
                "name": "Englewood Hospital and Medical Center"
            }, 
            "investigator": {
                "last_name": "Rosalyn Stahl, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "overall_contact": {
            "email": "Jamie.Ketas@ehmc.com", 
            "last_name": "Jamie Ketas", 
            "phone": "201-894-3418"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Breast Cancer sick population and healthy population. breast cancer.", 
            "safety_issue": "No", 
            "time_frame": "Upon enrollment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Rauscher, Gregory E., M.D. PA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rauscher, Gregory E., M.D. PA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}